These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8533671)

  • 21. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
    Schoenfield L; Jones JS; Zippe CD; Reuther AM; Klein E; Zhou M; Magi-Galluzzi C
    BJU Int; 2007 Apr; 99(4):770-4. PubMed ID: 17233800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluctuating prostate-specific antigen levels in patients with initial negative biopsy: should we be reassured?
    Celhay O; de la Taille A; Salomon L; Doré B; Irani J
    BJU Int; 2007 May; 99(5):1028-30. PubMed ID: 17324221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results.
    Cohen JK; Miller RJ; Rooker GM; Shuman BA
    Urology; 1996 Mar; 47(3):395-401. PubMed ID: 8633408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Repeat prostate biopsy in patients with previous negative biopsies].
    Nagata M; Sato T; Un-no T; Nagae H; Mugiya S; Takayama T; Suzuki K; Fujita K
    Hinyokika Kiyo; 2002 Oct; 48(10):589-92. PubMed ID: 12491609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies.
    Gilbert SM; Cavallo CB; Kahane H; Lowe FC
    Urology; 2005 Mar; 65(3):549-53. PubMed ID: 15780374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical analysis of patients with early-stage prostate cancer managed without initial treatment].
    Kawa G; Hiura Y; Satoh H; Sugi M; Fujita I; Oguchi N; Doi H; Ashida M; Okada H; Muguruma K; Murota T; Koyama Y; Kawamura H; Ohara T; Kawakita M; Matsuda T
    Hinyokika Kiyo; 2002 Mar; 48(3):133-8. PubMed ID: 11993205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
    Ornstein DK; Rao GS; Smith DS; Ratliff TL; Basler JW; Catalona WJ
    J Urol; 1997 Jan; 157(1):195-8. PubMed ID: 8976249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
    Loeb S; Roehl KA; Yu X; Han M; Catalona WJ
    Urology; 2007 Jan; 69(1):108-12. PubMed ID: 17270629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
    Harris CH; Dalkin BL; Martin E; Marx PC; Ahmann FR
    J Urol; 1997 May; 157(5):1740-3. PubMed ID: 9112517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.